"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
-
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
-
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
-
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019 Apr; 174(2):297-305.
-
Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells. Mol Cell. 2017 Mar 16; 65(6):1122-1135.e5.
-
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
-
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
-
Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells. PLoS One. 2015; 10(12):e0145061.
-
Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol. 2015 Dec 15; 418 Pt 3:240-4.
-
Estradiol and tamoxifen regulate NRF-1 and mitochondrial function in mouse mammary gland and uterus. J Mol Endocrinol. 2013 Oct; 51(2):233-46.